Enhancing Access to Lung Cancer Screening: UK NHS Professionals’ Insights

Overview

Lung cancer screening (LCS) using low-dose CT has demonstrated mortality reduction but faces low uptake in the UK NHS Lung Cancer Screening Programme (LCSP), especially among socioeconomically deprived groups. Professionals involved in LCSP delivery highlight barriers related to invitation strategies, eligibility criteria, and structural inequalities impacting equitable access.

Background

Lung cancer is the leading cause of cancer death globally, with smoking as the primary risk factor. Early-stage lung cancer is often asymptomatic, leading to late diagnosis and poor prognosis. The UK NHS LCSP, initiated in 2019 in high-risk areas, aims to expand population-wide by 2030. Despite proven mortality benefits of LDCT screening, uptake remains low compared to other cancer screening programmes, with significant disparities linked to socioeconomic deprivation and smoking status.

Data Highlights

Uptake rates for lung cancer screening in the UK NHS LCSP range from 20.4% to 52.6%, substantially lower than bowel (67.6%) and breast (70.7%) cancer screening programmes. Smoking prevalence and lung cancer incidence are higher in deprived areas, yet screening participation is lower in these groups. Eligibility criteria include age 55-74 years, GP registration, and smoking history, with exclusion for physical limitations and poor fitness.

Key Findings

• Professionals perceive that current invitation strategies may not adequately address barriers faced by socioeconomically deprived and high-risk populations.
• Structural inequalities, including deprivation and comorbidities, contribute to lower screening uptake despite higher lung cancer risk.
• Fear of cancer, fatalism, and mistrust of health professionals are significant psychological barriers to participation.
• Eligibility criteria and physical exclusion factors may inadvertently limit access for some high-risk individuals.
• There is a need for tailored, equitable approaches to invitation and engagement to improve coverage and reduce disparities.
• Operationalisation of accessibility goals in the LCSP protocol varies locally, indicating opportunities for standardisation and improvement.

Clinical Implications

Clinicians and programme implementers should consider multifaceted strategies to enhance lung cancer screening uptake, particularly targeting deprived and high-risk groups. Addressing psychological barriers and ensuring flexible, inclusive eligibility and invitation processes may improve equitable access. Early engagement with communities and integration of support for comorbidities could further facilitate participation.

Conclusion

The UK NHS LCSP shows promise in reducing lung cancer mortality but currently faces challenges in equitable access and uptake. Insights from professionals underscore the importance of addressing social determinants and operational barriers to optimise screening reach and impact.

References

1. NHS Lung Cancer Screening Programme (LCSP) 2019-2024 -- Programme Overview and Invitation Criteria
2. International Studies on Lung Cancer Screening Mortality Reduction 2011-2018
3. UK National Screening Committee (UK NSC) 2024 -- Screening Eligibility and Exclusion Criteria
4. Scoping Review on Lung Cancer Screening Uptake Barriers 2023